Type I IFNs additionally upregulate the Gal-9 binding immune checkpoint receptor, PD-1, on melanoma cells through the Janus kinase/signal transducer and activator of transcription (JAK/STAT) pathway [126]. Here, LGALS9 is linked to melanoma.